E.O. is on the speakers’ bureau for Bayer, Chugai Pharmaceutical, Eli Lilly, Ono Pharmaceutical, Taiho Pharmaceutical, Takeda Pharmaceutical, and Bristol-Myers; MS has a consulting/advisory role for Sysmex; S.Y. is on the speakers’ bureau for Chugai Pharmaceutical, Covidien, Eli Lilly, Merck Serono, Johnson & Johnson, and Taiho Pharmaceutical; N.T. received research funding from Chugai Pharmaceutical and Taiho Pharmaceutical; Y.H. received honoraria from Bayer, Chugai Pharmaceutical, Kaken Pharmaceutical, Merck Serono, Sanofi, Taiho Pharmaceutical, and Takeda Pharmaceutical, as well as research funding from Chugai Pharmaceutical, Kaken Pharmaceutical, Merck Serono, Sanofi, Taiho Pharmaceutical, and Takeda Pharmaceutical; S.T., T.M., and K.Y. are employed by Sysmex and have stock/other ownership in Sysmex; and E.S., M.I., S.H., Y.T., H.I., K.T., M.M., MS, M.T., H.O., S.O., and K.H. have no relationship to disclose.